more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$240.19 USD

+2.35 (0.99%)

Updated Jul 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

Bottom 19% (203 out of 251)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

BD (BDX) to Boost Pre-Fillable Syringe-Manufacturing Capacity

by Zacks Equity Research Published on December 03,2020

BD (BDX) is set to improve its pre-fillable syringe-manufacturing ability with its expansion and upgrade plans.

medical

Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus

by Zacks Equity Research Published on December 01,2020

Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic

medical

Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX

by Zacks Equity Research Published on November 13,2020

This should further boost BD's (BDX) Medical segment.

medical

Becton Dickinson (BDX) Earnings Surpass Estimates in Q4

by Zacks Equity Research Published on November 05,2020

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.

Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research Published on November 05,2020

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.60% and 6.68%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

BDXPositive Net Change

Medical Products' Nov 5 Earnings Roster: BDX, ABC & More

by Trina Mukherjee Published on November 04,2020

Medical Product companies have shown strength in the third quarter on the back of huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research Published on November 03,2020

Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.

Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on October 29,2020

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BDXPositive Net Change

3 Dental Supplies Stocks Set to Shine on the Industry's Upturn

by Trina Mukherjee Published on October 29,2020

Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.

medical

LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service

by Zacks Equity Research Published on October 26,2020

Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.

medical

BD's (BDX) COVID-19 Real-Time PCR Detection Kit Gets CE Mark

by Zacks Equity Research Published on October 23,2020

BD's (BDX) Real Time PCR Detection Kit enables BD MAX System users to run a single module that tests concurrently for COVID-19, flu and RSV.

OPKO Health's (OPK) BioReference Laboratories Unveils New Test

by Zacks Equity Research Published on October 23,2020

OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.

BD Gets 510(k) Clearance for Its FACSLyric Flow Cytometer

by Zacks Equity Research Published on October 06,2020

BD (BDX) gets 510(k) clearance from the FDA for its new integrated system that helps clinical laboratories to fully automate the sample to answer process and boost their efficiency.

medical

BD Gets CE Mark for Point-of-Care Coronavirus Antigen Test

by Zacks Equity Research Published on October 05,2020

BD (BDX) receives CE mark for its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System.

medical

Quest Diagnostics' 3-in-1 Coronavirus Test Launch Well Timed

by Zacks Equity Research Published on October 02,2020

According to Quest Diagnostics (DGX), under such situation, laboratory testing that can reliably identify the virus causing disease will be critical to mobilize effective patient care.